InterCure (INCR) Competitors

InterCure (NASDAQ:INCR) and Lifecore Biomedical (NASDAQ:LFCR) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment.

Is INCR or LFCR more profitable?

InterCure has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -31.70%. InterCure's return on equity of 0.00% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
Lifecore Biomedical	-31.70%	-846.51%	-13.03%

Which has stronger valuation & earnings, INCR or LFCR?

InterCure has higher earnings, but lower revenue than Lifecore Biomedical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$64.55M	N/A	-$18.32M	N/A	N/A
Lifecore Biomedical	$128.87M	2.14	-$38.72M	-$1.31	-5.63

Do institutionals & insiders believe in INCR or LFCR?

8.3% of InterCure shares are held by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are held by institutional investors. 0.2% of InterCure shares are held by company insiders. Comparatively, 32.2% of Lifecore Biomedical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Do analysts recommend INCR or LFCR?

Lifecore Biomedical has a consensus price target of $8.00, indicating a potential upside of 8.55%. Given Lifecore Biomedical's stronger consensus rating and higher possible upside, analysts plainly believe Lifecore Biomedical is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Lifecore Biomedical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Which has more risk and volatility, INCR or LFCR?

InterCure has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Comparatively, Lifecore Biomedical has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500.

Does the media prefer INCR or LFCR?

In the previous week, Lifecore Biomedical had 1 more articles in the media than InterCure. MarketBeat recorded 4 mentions for Lifecore Biomedical and 3 mentions for InterCure. Lifecore Biomedical's average media sentiment score of 0.38 beat InterCure's score of 0.29 indicating that Lifecore Biomedical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InterCure	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lifecore Biomedical	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Lifecore Biomedical beats InterCure on 8 of the 13 factors compared between the two stocks.